Unmet needs of multiple sclerosis patients in the community

Multiple Sclerosis and Related Disorders
Roisin LonerganNiall Tubridy

Abstract

There is no evidence that disease modifying therapies (DMTs) are beneficial in progressive (non-relapsing) MS. However, these patients may benefit from multidiscipliniary interventions, and require financial and community support. Non-pharmacological needs of MS patients may be overlooked during fund allocation, and identification of unmet needs is important to optimise care and inform governmental resource distribution. To identify unmet needs of MS patients in 3 areas during an Irish epidemiology study. Observational study in 3 regions in Ireland: South Dublin SCD (an urban area), Donegal DGL and Wexford WEX (rural counties).A validated Needs Assessment Questionnaire (NAQ) was completed by MS patients at research clinics, or by telephone if unable to attend. We identified 632 patients with multiple sclerosis: 23% SCD (urban), 30.8% WEX, and 46.2% DGL.MS subtype was relapsing remitting (RR) in 51.1%, secondary progressive (SP) in 39.7%, and primary progressive (PP) in 9.2%. EDSS was </=6 in 86% and >6.5 in 14%. NAQ was completed by 325 (49.9%).Group A: 155 (47.7%) reported no unmet needs relating to MS.Group B: 170 (52.3%) reported unmet needs relating to MS,including all in a group continuing to use disease-modifying therapy ...Continue Reading

References

Jan 9, 1993·BMJ : British Medical Journal·M H Williams, C Bowie
Aug 1, 1997·Annals of Neurology·J A FreemanA J Thompson
Feb 25, 2000·Clinical Rehabilitation·S J Smith, C A Young
Nov 18, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·J A Freeman, A J Thompson
Feb 13, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·C M WilesA Morgan
Nov 12, 2005·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Mar 31, 2007·Journal of Advanced Nursing·Angus ForbesMelissa Taylor
Jul 7, 2007·Multiple Sclerosis : Clinical and Laboratory Research·F PattiUNKNOWN Italian Study Group On Quality Of Life In Ms
Jul 26, 2008·Multiple Sclerosis : Clinical and Laboratory Research·R VazirinejadC Ward
Dec 17, 2009·Multiple Sclerosis : Clinical and Laboratory Research·Claudia Christina Hilt PflegerNils Koch-Henriksen
Jan 21, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·R LonerganN Tubridy

❮ Previous
Next ❯

Citations

Sep 28, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Arie GafsonPaul M Matthews
Feb 28, 2019·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Michela PonzioMichele Messmer Uccelli
Oct 24, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Per Soelberg SorensenGiancarlo Comi
Nov 27, 2019·Neurodegenerative Disease Management·Jiwon OhCatherine Larochelle
Aug 7, 2021·Journal of Personalized Medicine·Alessandra BujaGianfranco Damiani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.